WHAT’S IN A NAME?: WHY NOVARTIS WON AN INJUNCTION AGAINST NOVITAS
The case of Novartis AG & Anr. v. Novitas Lifesciences & Anr.[1] revolves around a trademark dispute where Novartis, a globally recognized pharmaceutical company, has […]
Articles by Krishnam Goyal
THE IP PRESS LAW REVIEW VOL. 1 ISSUE 1
The IP Press Law Review (IPPLR) is an initiative of The IP Press to extend our objectives of spreading awareness on the issues concerning intellectual […]
Quick reference to 7days 7 Blogs on sports law- National Sports Day
Gender Discrimination in Sports- How long must we wait for equality?Authored by: Hetvi TrivediRead the full article here. PV Sindhu and interplay of moment marketing, […]
Prior user right in patent law
No! Don’t confuse the title of this post “rights of a prior user” with the “prior user” of the Indian trademark law. Here we are […]
Invitation to join the IP workshop
Join us on 27th September to become a part of an excellent workshop on Intellectual Property Rights. The workshop will be conducted by the expert […]
Global ‘FRAND’liness (license) over a standardized technology: is it a reality?
The German court (Mannheim) recently allowed an injunction in favor of Nokia to prevent Daimler from the unauthorized use of their SEP in Germany. The […]
Nokia V Daimler: Another SEP litigation to discuss!!!
After writing an introductory post on SEP licensing and discussing the steps of SEP licensing negotiation in view of the German case Haier v. Sisvel, […]
Inventions by AI machines fighting for recognition: The return of DABUS
Last year, the EPO made a loud noise by rejecting a patent application over an invention produced by an AI machine named DABUS. The legal […]
Basics of SEP in light of the recent German court’s decision
I have earlier researched, discussed and talked about Standard Essential Patents (SEP), however, I have never penned down my thoughts on this topic until now! […]
Public disclosure of the invention is safer than a secret use: Loopholes in the patent law
Secret use of an invention before filing a patent application could amount to public use and such public use of the invention would be beyond […]
Monsanto’s patent took its last breath, undetermined if it was a patent or plant variety
The present blog pertains to the landmark fight over Monsanto’s Bt. Cotton technology. It is not yet finalised whether the subject invention was a patentable […]
WIPO PROOF: An online tamper-proof wallet to record trade secrets and other intellectual assets
On May 27, 2020, WIPO launched a service that would provide evidence of the existence of intellectual assets at a specific point in time. This […]
Fast track patenting in India: An overview of IPO-JPO Patent Prosecution Highway (PPH) Pilot Program
Fast track patenting in India is slowly becoming a trend now. Starting with a first set of initiatives to fast track examinations of patent applications […]
Did Apple steal the trade secrets of a startup?
The liquid flows from higher concentration to lower. Is it the same for the flow of information [trade secrets] from higher concentration companies to startups? […]
USPTO’s COVID-19 Prioritized Examination Pilot Program
“Independent inventors and small businesses are often the difference-makers when it comes to cutting-edge innovation and the growth of our economy. They are also in […]
Interpretation of Art. 53(b) of the European Patent Convention inches closer to the interpretation of Section 3(j) of the Indian patents act, 1970
On May 14, 2020, the Enlarged Board of Appeals of the European Patent Organisation (EPO) has issued an opinion [click to access] about the interpretation […]
Public health lawfully outlaws the patent rights: a story of March-in rights!
My previous posts on the open-source innovation read with Doha style compulsory licensing and revocation in the public interest were exhaustive on the access to […]
USPTO initiates an online platform for voluntary licensing
A new web-based intellectual property (IP) marketplace platform, Patents 4 Partnerships, is introduced by USPTO on May 4, 2020. It provides the searchable database of patents […]
From the bolar provision to the issuance of the compulsory license and revocation in the public interest – Remdesivir drug of Gilead is a complete course on patent law
The time since the experts have suggested “Remdesivir” as a possible drug to fight against COVID-19, global debate over obtaining this drug is started. The […]
Open Source Innovation in the pharmaceuticals: Is that all for public health?
Dear Readers, I hope you are reading this post in your good health and essentially operable outdoor conditions. In this unfortunate time, when the world […]